These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 8643611)

  • 1. Dopamine transporters are markedly reduced in Lesch-Nyhan disease in vivo.
    Wong DF; Harris JC; Naidu S; Yokoi F; Marenco S; Dannals RF; Ravert HT; Yaster M; Evans A; Rousset O; Bryan RN; Gjedde A; Kuhar MJ; Breese GR
    Proc Natl Acad Sci U S A; 1996 May; 93(11):5539-43. PubMed ID: 8643611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine transporter changes in neuropsychiatric disorders.
    Wong DF; Ricaurte G; Gründer G; Rothman R; Naidu S; Singer H; Harris J; Yokoi F; Villemagne V; Szymanski S; Gjedde A; Kuhar M
    Adv Pharmacol; 1998; 42():219-23. PubMed ID: 9327883
    [No Abstract]   [Full Text] [Related]  

  • 3. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease.
    Frost JJ; Rosier AJ; Reich SG; Smith JS; Ehlers MD; Snyder SH; Ravert HT; Dannals RF
    Ann Neurol; 1993 Sep; 34(3):423-31. PubMed ID: 8363363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
    Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Sakamoto M
    Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term methamphetamine-induced decreases of [(11)C]WIN 35,428 binding in striatum are reduced by GDNF: PET studies in the vervet monkey.
    Melega WP; Lacan G; Desalles AA; Phelps ME
    Synapse; 2000 Mar; 35(4):243-9. PubMed ID: 10657033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428.
    Wong DF; Yung B; Dannals RF; Shaya EK; Ravert HT; Chen CA; Chan B; Folio T; Scheffel U; Ricaurte GA
    Synapse; 1993 Oct; 15(2):130-42. PubMed ID: 8259524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression of changes in dopamine transporter binding site density as a result of cocaine self-administration in rhesus monkeys.
    Letchworth SR; Nader MA; Smith HR; Friedman DP; Porrino LJ
    J Neurosci; 2001 Apr; 21(8):2799-807. PubMed ID: 11306632
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain.
    Madras BK; Gracz LM; Fahey MA; Elmaleh D; Meltzer PC; Liang AY; Stopa EG; Babich J; Fischman AJ
    Synapse; 1998 Jun; 29(2):116-27. PubMed ID: 9593102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.
    Nurmi E; Ruottinen HM; Kaasinen V; Bergman J; Haaparanta M; Solin O; Rinne JO
    Ann Neurol; 2000 Jun; 47(6):804-8. PubMed ID: 10852547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in dopamine availability in the nigrostriatal and mesocortical dopaminergic systems by gait in Parkinson's disease.
    Ouchi Y; Kanno T; Okada H; Yoshikawa E; Futatsubashi M; Nobezawa S; Torizuka T; Tanaka K
    Brain; 2001 Apr; 124(Pt 4):784-92. PubMed ID: 11287377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters.
    Fischman AJ; Bonab AA; Babich JW; Palmer EP; Alpert NM; Elmaleh DR; Callahan RJ; Barrow SA; Graham W; Meltzer PC; Hanson RN; Madras BK
    Synapse; 1998 Jun; 29(2):128-41. PubMed ID: 9593103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presynaptic dopaminergic deficits in Lesch-Nyhan disease.
    Ernst M; Zametkin AJ; Matochik JA; Pascualvaca D; Jons PH; Hardy K; Hankerson JG; Doudet DJ; Cohen RM
    N Engl J Med; 1996 Jun; 334(24):1568-72. PubMed ID: 8628337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of detached personality in healthy subjects by low dopamine transporter binding.
    Laakso A; Vilkman H; Kajander J; Bergman J; paranta M; Solin O; Hietala J
    Am J Psychiatry; 2000 Feb; 157(2):290-2. PubMed ID: 10671406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography of striatal serotonin transporters in Parkinson disease.
    Kerenyi L; Ricaurte GA; Schretlen DJ; McCann U; Varga J; Mathews WB; Ravert HT; Dannals RF; Hilton J; Wong DF; Szabo Z
    Arch Neurol; 2003 Sep; 60(9):1223-9. PubMed ID: 12975287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa.
    Poyot T; Condé F; Grégoire MC; Frouin V; Coulon C; Fuseau C; Hinnen F; Dollé F; Hantraye P; Bottlaender M
    J Cereb Blood Flow Metab; 2001 Jul; 21(7):782-92. PubMed ID: 11435790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Baldwin RM; Zoghbi S; Zea-Ponce Y; Charney DS; van Dyck CH; Hoffer PB; Innis RB
    J Nucl Med; 1997 Sep; 38(9):1453-9. PubMed ID: 9293807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graphical, kinetic, and equilibrium analyses of in vivo [123I] beta-CIT binding to dopamine transporters in healthy human subjects.
    Laruelle M; Wallace E; Seibyl JP; Baldwin RM; Zea-Ponce Y; Zoghbi SS; Neumeyer JL; Charney DS; Hoffer PB; Innis RB
    J Cereb Blood Flow Metab; 1994 Nov; 14(6):982-94. PubMed ID: 7929662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET.
    Sekine Y; Iyo M; Ouchi Y; Matsunaga T; Tsukada H; Okada H; Yoshikawa E; Futatsubashi M; Takei N; Mori N
    Am J Psychiatry; 2001 Aug; 158(8):1206-14. PubMed ID: 11481152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal dopamine nerve terminal markers but not nigral cellularity are reduced in spinocerebellar ataxia type 1.
    Kish SJ; Guttman M; Robitaille Y; el-Awar M; Chang LJ; Levey AI
    Neurology; 1997 Apr; 48(4):1109-11. PubMed ID: 9109912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altropane, a SPECT or PET imaging probe for dopamine neurons: II. Distribution to dopamine-rich regions of primate brain.
    Madras BK; Gracz LM; Meltzer PC; Liang AY; Elmaleh DR; Kaufman MJ; Fischman AJ
    Synapse; 1998 Jun; 29(2):105-15. PubMed ID: 9593101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.